title: Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy.
abstract: The present study investigated immune restoration in patients at intermediate stages of human immunodeficiency virus (HIV) disease after initiation of highly active antiretroviral therapy (HAART). A progressive increase in both memory and naive CD4+ T cells was observed from the first weeks of therapy, concomitant with a decrease in the expression of activation markers on CD8+ T cells. The early-activation marker CD69 remained, however, overexpressed on T cells after suboptimal stimulation in vitro, indicative of persistent immune activation. The percentage of interleukin (IL)-2-producing CD4+ T cells significantly increased from 9 months of HAART. In most patients, CD4+ T cells recovered an ability to produce IL-2 on stimulation, similar to that of HIV-seronegative controls. Reversal of T-cell anergy may be a key event in immune restoration for achieving long-term clinical benefit with HAART.
authors.affiliation: INSERM U 430, Hôpital Broussais, 75014, Paris, France. laurence. weiss@brs.ap-hop-paris.fr
authors.forename: L
authors.initials: L
authors.lastname: Weiss
authors.forename: P
authors.initials: P
authors.lastname: Ancuta
authors.forename: P M
authors.initials: PM
authors.lastname: Girard
authors.forename: H
authors.initials: H
authors.lastname: Bouhlal
authors.forename: A
authors.initials: A
authors.lastname: Roux
authors.forename: N H
authors.initials: NH
authors.lastname: Cavaillon
authors.forename: M D
authors.initials: MD
authors.lastname: Kazatchkine
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood; D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007156:Immunologic Memory; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000096:biosynthesis*; D037181:Lectins, C-Type; D008213:Lymphocyte Activation; D008875:Middle Aged; D015166:Monitoring, Immunologic; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D000998:Antiviral Agents; D015415:Biomarkers; D007376:Interleukin-2; D037181:Lectins, C-Type; D000099192:CD69 Antigens